Our findings reveal that soluble AZGP1 acts as a predictive biomarker for 5-FU efficacy in cholangiocarcinoma and exerts pro-apoptotic and immunomodulatory functions via interaction with PD-L1. The gene discussed is CD274; the disease is cholangiocarcinoma.